Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61883 | 0.83 | PLK4 (0.53) | PLK4PAK4PDE2ABTKSMN1; SMN2 | |
| SCHEMBL30008432 | 0.79 | PLK4 (0.33) | PLK4PAK4 | |
| SCHEMBL341706 | 0.79 | ADORA2A (0.47) | PLK4PAK4XDHRETPI4KA | |
| SCHEMBL166657 | 0.79 | PLK4 (0.42) | PLK4PAK4XDHSMN1; SMN2ADORA2A | |
| SCHEMBL2266999 | 0.79 | PLK4 (0.45) | PLK4PAK4PDE2ABTKXDH | |
| SCHEMBL31439112 | 0.79 | NOS1 (0.37) | PLK4PAK4PDE2AXDHRET | |
| SCHEMBL12398424 | 0.79 | PLK4 (0.36) | PLK4PAK4XDHRETPI4KA | |
| SCHEMBL560806 | 0.79 | RET (0.52) | PLK4PAK4PDE2ABTKXDH | |
| Hydrochloric Acid SCHEMBL5003526 | 0.78 | PLK4 (0.41) | PLK4PAK4XDHSMN1; SMN2ADORA2A | |
| SCHEMBL8095697 | 0.78 | PLK4 (0.55) | PLK4PAK4PDE2ABTKXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010011620-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-28 | — | — | WO | claimed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | claimed |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-117683033-B | Substituted alkynyl heterocyclic compounds | Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117466964-B | Nucleoside diphosphate compound and preparation method thereof | 南京烁慧医药科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12577272-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260042794-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3964518-B1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4674481-A2 | CD73 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1772454-A1 | NITROGENOUS FUSED BICYCLIC COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2007-04-11 | — | — | EP | disclosed |
| EP-0673376-B1 | BICYCLIC PYRIMIDINE COMPOUNDS, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | ADIR (FR) | 1996-05-22 | — | — | EP | disclosed |
| US-5508277-A | Bicyclic pyrimidines | ADIR ET COMPAGNIE (FR) | 1996-04-16 | — | — | US | disclosed |
| EP-0673376-A1 | NOVEL BICYCLIC PYRIMIDINE COMPOUNDS, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS. | ADIR (FR) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013668-A1 | NOVEL BICYCLIC PYRIMIDINE COMPOUNDS, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | ADIR ET COMPAGNIE (FR) | 1994-06-23 | — | — | WO | disclosed |
| EP-0168730-A2 | Process for forming direct positive images, direct positive silver halide elements, compositions and compounds as characteristic feature of such processes and elements | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577272-B2 | CD73 inhibitors | NT5E, ADORA2A, NTPCR | PLK4 4713/4885PAK4 4720/4885PDE2A 679/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | PLK4 864/4885PAK4 2043/4885PDE2A 2623/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | PLK4 512/4885PAK4 325/4885PDE2A 1933/4885 |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | PLK4 138/4885PAK4 60/4885PDE2A 1598/4885 |
| US-20260042794-A1 | CD73 INHIBITORS | NT5E, ENTPD5, ENTPD1 | PLK4 2405/4885PAK4 2205/4885PDE2A 298/4885 |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | NTPCR, NT5C2, NT5E | PLK4 4780/4885PAK4 4658/4885PDE2A 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.